ADCs consist of highly potent cytotoxic agents conjugated to antibodies through a specific linker. This molecular format enables the highly selective delivery of any payload to the diseased tissue, while healthy parts of the human body are spared. To date, ADCs generated with conventional methods have faced the following challenges:
We are pioneering a technology enabling fast and precise production of ADCs. Our innovative approach has the potential to set new benchmarks in terms of development, analysis and performance. The following properties contribute to the high efficacy and low level of toxicity observed so far with our ADCs:
No need for engineering or antibody reduction.
This may lead to lower dosing, higher efficacy and lower risk for side effects.
As the inventor of the Araris Linker Technology, Philipp has a profound background in Bioconjugation and ADCs. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris Linker Technology.
Isabella holds a Master’s Degree in Molecular Biology from University of Basel and obtained a PhD in Tumorimmunology from University of Zurich (UZH). Before joining Araris, she served as Director Pharmacology at Covagen, a Swiss Biotech that was acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical companies of Johnson & Johnson. She was in charge of the pharmacological characterization of various FynomAbs during pre-clinical development that entered clinical testing.
Dragan received his Master’s degree and PhD in Pharmaceutical Sciences from ETH Zürich. From 2007 to 2014 he was co-founder and CSO of Covagen, a Swiss biotech company acquired in 2014 by an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. He was instrumental in Covagen’s trade sale to Johnson & Johnson, in establishing deals with Roche and Mitsubishi Tanabe and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014. Since 2015 he is a serial entrepreneur and Biotech consultant at Grabulovski Consulting Services.
Araris announces closing of CHF2.5M seed financing round with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners.
The Venture Kick jury awards MOBBOT and Araris Biotech 130,000 francs each to accelerate the engineering startup and drug-discovery spin-off's speed-to-market. The Swiss startups’ innovations in material science and biotech will benefit the construction and pharmaceutical industries.
Araris presents first data on their proprietary ADC linker technology at AACR in Atlanta, 2019.